In The News Posted May 21, 2019 Share Posted May 21, 2019 NEW YORK, May 21, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the expansion of the core investigator group supporting clinical and regulatory pathways for FractalDx, a portfolio... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.